Hubly Surgical Receives 510k Clearance from FDA to Market Innovative Cranial Access Drill for Neurosurgical Safety in the ICU

Summation

  • Hubly Surgical announced today that they received 510k clearance from the FDA to market the Hubly Drill, an innovative medical technology developed with the goal of making burr hole procedures safer and more efficient in any setting, including outside of the operating room.
  • The Hubly Drill aims to mitigate the challenges of bedside cranial access by being the first and only cordless single-use cranial drill with advanced features for safety and efficiency in any setting.
  • These procedures are frequently performed outside of the operating room in emergencies, yet the current bedside procedure relies on an inaccurate device, deficient in safety and efficiency features.

Hubly Surgical announced today that they received 510k clearance from the FDA to market the Hubly Drill, an innovative medical technology developed with the goal of making burr hole procedures safer and more efficient in any setting, including outside of the operating room.

A burr hole procedure is the prerequisite brain surgery for any time a physician needs to access the brain. This is done for patients with traumatic brain injury, hydrocephalus, ruptured aneurysm, stroke, subdural hematoma, epilepsy, Parkinson’s, and brain cancer and tumors. These procedures are frequently performed outside of the operating room in emergencies, yet the current bedside procedure relies on an inaccurate device, deficient in safety and efficiency features.

“Burr holes are one of the most common neurosurgical procedures we perform,” said Dr. Matthew Potts, a Cerebrovascular Neurosurgeon and Assistant Professor at Northwestern. “And at the bedside, they are often done using a cumbersome hand-cranked drill. I know first-hand how antiquated this solution is and how dangerous this procedure can be. I’m excited that Hubly has developed an improved intracranial drill for burr-hole placement.”

The Hubly Drill aims to mitigate the challenges of bedside cranial access by being the first and only cordless single-use cranial drill with advanced features for safety and efficiency in any setting. “Essentially we are bringing the precision of the operating room, which physicians are accustomed to, to the bedside,” said Founder/CEO Casey Grage.

The technology features novel innovations for safety and efficiency, including SMART Auto-Stop with a proprietary drill bit designed to reduce over-plunge (a common problem with the current standard of care). There is also a first-of-its-kind LED Force Indicator that changes color with force, increasing user control.

Grage added, “We believe the facilities that add the Hubly Drill into their workflow will recognize significant value by reducing operating room dependence and increasing access at the bedside, thus lowering hospital costs.”

Other FDA News of Interest

Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes

"Unauthorized e-cigarettes and vaping products continue to jeopardize the health of Americans – particularly children and adolescents – across the country," said Acting Associate Attorney General Benjamin C. Mizer. "This interagency Task Force is dedicated to protecting Americans by combatting the unlawful sale and distribution of these products. And the establishment of this Task Force makes clear that vigorous enforcement of the tobacco laws is a government-wide priority."

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older. The first non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

By using this website you agree to accept Medical Device News Magazine Privacy Policy